ATE328590T1 - Pharmazeutische zusammensetzungen enthaltend s-(- )-n-propargyl-1-aminoindan - Google Patents

Pharmazeutische zusammensetzungen enthaltend s-(- )-n-propargyl-1-aminoindan

Info

Publication number: ATE328590T1
Authority: AT; Austria
Prior art keywords: pharmaceutical compositions; aminoindane; propargyl; disease; compositions containing
Prior art date: 1996-07-11

Application number

AT97927353T

Other languages

English (en)

Inventor

Ruth Levy

Moussa B H Youdim

John P M Finberg

Sasson Cohen

Jeff Sterling

Original Assignee

Teva Pharma

Technion Res & Dev Foundation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-07-11

Filing date

1997-06-20

Publication date

2006-06-15

1997-06-20 Application filed by Teva Pharma, Technion Res & Dev Foundation filed Critical Teva Pharma

2006-06-15 Application granted granted Critical

2006-06-15 Publication of ATE328590T1 publication Critical patent/ATE328590T1/de

Links

239000008194 pharmaceutical composition Substances 0.000 title abstract 3
208000014674 injury Diseases 0.000 abstract 4
208000027418 Wounds and injury Diseases 0.000 abstract 3
230000006378 damage Effects 0.000 abstract 3
206010021143 Hypoxia Diseases 0.000 abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
206010002660 Anoxia Diseases 0.000 abstract 1
241000976983 Anoxia Species 0.000 abstract 1
206010019196 Head injury Diseases 0.000 abstract 1
208000028389 Nerve injury Diseases 0.000 abstract 1
208000012902 Nervous system disease Diseases 0.000 abstract 1
208000018737 Parkinson disease Diseases 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
230000007953 anoxia Effects 0.000 abstract 1
230000007954 hypoxia Effects 0.000 abstract 1
230000008764 nerve damage Effects 0.000 abstract 1
230000004770 neurodegeneration Effects 0.000 abstract 1
208000015122 neurodegenerative disease Diseases 0.000 abstract 1
230000000926 neurological effect Effects 0.000 abstract 1
231100000189 neurotoxic Toxicity 0.000 abstract 1
230000002887 neurotoxic effect Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
230000008733 trauma Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
- C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT97927353T 1996-07-11 1997-06-20 Pharmazeutische zusammensetzungen enthaltend s-(- )-n-propargyl-1-aminoindan ATE328590T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IL11883696A IL118836A (en)	1996-07-11	1996-07-11	Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan

Publications (1)

Publication Number	Publication Date
ATE328590T1 true ATE328590T1 (de)	2006-06-15

Family

ID=11069065

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97927353T ATE328590T1 (de)	1996-07-11	1997-06-20	Pharmazeutische zusammensetzungen enthaltend s-(- )-n-propargyl-1-aminoindan

Country Status (12)

Country	Link
US (1)	US6277886B1 (de)
EP (1)	EP0929298B1 (de)
JP (1)	JP4368421B2 (de)
CN (1)	CN1149985C (de)
AT (1)	ATE328590T1 (de)
AU (1)	AU3188097A (de)
CA (1)	CA2260037C (de)
DE (1)	DE69736066T2 (de)
HU (1)	HU226961B1 (de)
IL (1)	IL118836A (de)
NO (1)	NO326052B1 (de)
WO (1)	WO1998002152A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5744500A (en) *	1990-01-03	1998-04-28	Teva Pharmaceutical Industries, Ltd.	Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL118836A (en)	1996-07-11	2001-01-11	Teva Pharma	Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
AU2002244247B2 (en)	2001-03-01	2007-12-13	Harbor Biosciences, Inc.	Use of certain steroids for treatment of blood cell deficiencies
US20040138187A1 (en)	2002-08-28	2004-07-15	Reading Christopher L.	Therapeutic treatment methods
JP4757024B2 (ja) *	2002-11-07	2011-08-24	テクニオンリサーチアンドディベラップメントファウンデイションリミテッド	神経保護鉄キレート剤及びそれを含む医薬組成物
US7396860B2 (en)	2002-11-15	2008-07-08	Teva Pharmaceutical Industries, Ltd.	Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
CA2547053C (en) *	2003-11-25	2014-05-27	Technion Research & Development Foundation Ltd.	Compositions and methods for treatment of cardiovascular disorders and diseases
US8097608B2 (en) *	2003-11-25	2012-01-17	Technion Research And Development Foundation Ltd.	Methods for treatment of cardiovascular disorders and diseases
JP2005232148A (ja) *	2004-02-03	2005-09-02	Technion Research & Development Foundation Ltd	神経保護剤としてプロパルギルアミンの使用
WO2006014973A2 (en) *	2004-07-26	2006-02-09	Teva Pharmaceutical Industries, Ltd.	Pharmaceutical dosage forms including rasagiline
US20060025446A1 (en) *	2004-07-27	2006-02-02	Jeffrey Sterling	Propargyl nitroxides and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders
AU2005330504B2 (en)	2004-09-29	2010-10-28	Harbor Biosciences, Inc.	Steroid analogs and characterization and treatment methods
PT1848415E (pt) *	2005-02-17	2013-06-27	Teva Pharma	Terapia de combinação com acetato de glatirâmero e rasagilina para o tratamento da esclerose múltipla
KR20170023211A (ko)	2005-02-23	2017-03-02	테바 파마슈티컬 인더스트리즈 리미티드	함량 균일성이 개선된 라사길린 제형
US8263655B2 (en)	2005-10-06	2012-09-11	Technion Research And Development Foundation Ltd	Methods for treatment of renal failure
WO2007061717A2 (en)	2005-11-17	2007-05-31	Teva Pharmaceutical Industries, Ltd.	Methods for isolating propargylated aminoindans
US7572834B1 (en)	2005-12-06	2009-08-11	Teva Pharmaceutical Industries, Ltd.	Rasagiline formulations and processes for their preparation
EP1956904B1 (de)	2005-12-09	2017-04-12	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.	Niedrig dosierter ladostigil zur behandlung von leichter kognitiver beeinträchtigung
JP5701485B2 (ja)	2006-02-21	2015-04-15	テバファーマシューティカルインダストリーズリミティド	多系統萎縮症の治療のためのラサギリンの使用
TW200744576A (en)	2006-02-24	2007-12-16	Teva Pharma	Propargylated aminoindans, processes for preparation, and uses thereof
JP5769923B2 (ja)	2006-04-03	2015-08-26	テバファーマシューティカルインダストリーズリミティド	レストレスレッグス症候群の治療のためのラサギリンの使用
EP1892233A1 (de) *	2006-08-18	2008-02-27	Ratiopharm GmbH	Neue Salze des Wirkstoffs Rasagilin
KR101077835B1 (ko) *	2006-12-14	2011-10-28	테바 파마슈티컬 인더스트리즈 리미티드	라사길린의 타닌산염
AU2007334428B2 (en) *	2006-12-14	2014-05-29	Teva Pharmaceutical Industries, Ltd.	Crystalline solid rasagiline base
EP1987816A1 (de) *	2007-04-30	2008-11-05	Ratiopharm GmbH	Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
AU2008296908B2 (en) *	2007-09-05	2014-01-09	Teva Pharmaceutical Industries, Ltd.	Method of treating glaucoma using rasagiline
US8188149B2 (en) *	2007-09-17	2012-05-29	Teva Pharmaceutical Industries, Ltd.	Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
SG187455A1 (en) *	2008-01-11	2013-02-28	Teva Pharma	Rasagiline formulations, their preparation and use
US20110027354A1 (en) *	2008-04-01	2011-02-03	Kim Hyoung-Chun	Anti-parkinsonian compounds
US20100008983A1 (en) *	2008-06-10	2010-01-14	Muhammad Safadi	Rasagiline soft gelatin capsules
EA201170018A1 (ru) *	2008-06-13	2011-08-30	Тева Фармасьютикал Индастриз, Лтд.	Разагилин для изменения течения болезни паркинсона
JP2011524907A (ja)	2008-06-19	2011-09-08	テバファーマシューティカルインダストリーズリミティド	固体ラサギリン塩基を調製および乾燥する方法
JP2011525489A (ja) *	2008-06-19	2011-09-22	テバファーマシューティカルインダストリーズリミティド	ラサリジン塩基の精製方法
US20100189791A1 (en) *	2009-01-23	2010-07-29	Teva Pharmaceutical Industries, Ltd.	Delayed release rasagiline malate formulation
PL2451771T3 (pl)	2009-07-09	2014-12-31	Ratiopharm Gmbh	Sole rasagiliny i ich preparaty farmaceutyczne
KR101791715B1 (ko)	2010-02-03	2017-10-30	파마 투 비 엘티디	라사길린의 연장 방출 제형 및 그 용도
JP2013537530A (ja)	2010-07-27	2013-10-03	テバファーマシューティカルインダストリーズリミティド	ラサギリンシトレートの分散物
AU2011282720B2 (en)	2010-07-27	2016-12-22	Teva Pharmaceutical Industries Ltd.	Use of rasagiline for the treatment of olfactory dysfunction
MX2014004201A (es)	2011-10-10	2015-01-12	Teva Pharma	R(+)-n-metil-propargil-aminoindano.
JP2014534196A (ja)	2011-10-10	2014-12-18	テバファーマシューティカルインダストリーズリミティド	Ｒ（＋）−ｎ−ホルミル−プロパルギル−アミノインダン
BR112015003451A2 (pt)	2012-08-17	2017-07-04	Teva Pharma	formulação parentérica de rasagilina
CN104177611A (zh) *	2013-05-27	2014-12-03	韩文毅	一种非线性的聚合物及其制备和用途
CN104177610A (zh) *	2013-05-27	2014-12-03	韩文毅	一种非线性的聚合物及其制备和用途
CN111333517A (zh) *	2018-12-19	2020-06-26	上海奥博生物医药技术有限公司	一种制备雷沙吉兰的改进方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1187017A (en) *	1966-07-16	1970-04-08	Aspro Nicholas Ltd	Substituted 1-Amino Indanes and Tetrahydronaphthalens
US5744500A (en) *	1990-01-03	1998-04-28	Teva Pharmaceutical Industries, Ltd.	Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) *	1990-01-03	1994-06-24	Teva Pharma	R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
IL112819A (en) *	1991-10-16	2001-11-25	Teva Pharma	Fluorinated 1-aminoindan compounds and a process for their preparation
IL111240A (en) *	1993-10-18	2001-10-31	Teva Pharma	Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
AU1867095A (en) *	1994-01-10	1995-08-01	Technion Research & Development Foundation Ltd.	1-aminoindan derivatives and compositions thereof
IL115357A (en) *	1995-09-20	2000-01-31	Teva Pharma	Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en)	1996-07-11	2001-01-11	Teva Pharma	Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan

1996
- 1996-07-11 IL IL11883696A patent/IL118836A/xx not_active IP Right Cessation
1997
- 1997-06-20 HU HU9904525A patent/HU226961B1/hu unknown
- 1997-06-20 JP JP50580698A patent/JP4368421B2/ja not_active Expired - Lifetime
- 1997-06-20 AU AU31880/97A patent/AU3188097A/en not_active Abandoned
- 1997-06-20 WO PCT/IL1997/000205 patent/WO1998002152A1/en not_active Ceased
- 1997-06-20 EP EP97927353A patent/EP0929298B1/de not_active Expired - Lifetime
- 1997-06-20 AT AT97927353T patent/ATE328590T1/de not_active IP Right Cessation
- 1997-06-20 CN CNB971971994A patent/CN1149985C/zh not_active Expired - Lifetime
- 1997-06-20 CA CA002260037A patent/CA2260037C/en not_active Expired - Lifetime
- 1997-06-20 DE DE69736066T patent/DE69736066T2/de not_active Expired - Lifetime
1999
- 1999-01-08 NO NO19990088A patent/NO326052B1/no not_active IP Right Cessation
- 1999-01-11 US US09/228,153 patent/US6277886B1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
HUP9904525A2 (hu)	2000-11-28
WO1998002152A1 (en)	1998-01-22
AU3188097A (en)	1998-02-09
US6277886B1 (en)	2001-08-21
IL118836A (en)	2001-01-11
CN1227486A (zh)	1999-09-01
DE69736066D1 (de)	2006-07-20
JP2000514453A (ja)	2000-10-31
EP0929298B1 (de)	2006-06-07
NO990088D0 (no)	1999-01-08
HU226961B1 (en)	2010-03-29
NO990088L (no)	1999-03-10
HUP9904525A3 (en)	2000-12-28
CA2260037C (en)	2007-01-23
CN1149985C (zh)	2004-05-19
DE69736066T2 (de)	2006-12-28
NO326052B1 (no)	2008-09-08
EP0929298A1 (de)	1999-07-21
JP4368421B2 (ja)	2009-11-18
CA2260037A1 (en)	1998-01-22
IL118836A0 (en)	1996-10-31

Legal Events

Date	Code	Title	Description
2006-12-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE328590T1 (de)	2006-06-15	Pharmazeutische zusammensetzungen enthaltend s-(- )-n-propargyl-1-aminoindan
HU913447D0 (en)	1992-01-28	Medical preparations and their use in treating neurologic disorders
GB2254784B (en)	1994-11-16	Film-coated solid dosage form of anti-migraine drug
WO2001009118A3 (en)	2001-11-22	Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
WO2002042462A3 (en)	2003-06-19	Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
UA41906C2 (uk)	2001-10-15	Спосіб лікування неврологічних порушень, викликаних травмами
NL300205I2 (nl)	2006-03-01	N-enentiomeer van N-propargyl-1-aminoindaan voor de behandeling van
MY130145A (en)	2007-06-29	Quinuclidine derivative for treatment of inflammatory and gastrointestinal disorders.
MX9708977A (es)	1998-03-31	Uso de r-enantiomero de sales de n-propargilo-1-aminoindano, y composiciones de las mismas.
CA2122058A1 (en)	1993-05-27	Tgf-beta to improve neural outcome
CA2111836A1 (en)	1992-12-23	Spin-trapping pharmaceutical compositions and methods for use thereof
MX9603489A (es)	1997-03-29	Peptidos opiodes novedosos para el tratamiento del dolor y uso de los mismos.
CA2148194A1 (en)	1995-10-31	Cyclopeptides of the formula i
CA2143610A1 (en)	1994-04-14	Use of norastemizole for the treatment of allergic disorders
ATE202709T1 (de)	2001-07-15	Zusammensetzungen die g-csf und ein tnf- bindungsprotein enthalten
YU49215B (sh)	2004-11-25	Primena flupirtina za dobijanje medikamenta za tretman neurodegenerativnih oboljenja
DE69835435D1 (de)	2006-09-14	Anti-arrhythmische zusammensetzungen und behandlungsverfahren
CA2374997A1 (en)	2000-12-28	Il6ril6 chimera for the treatment of neurodegenerative diseases
MXPA01009384A (es)	2004-03-19	Composiciones farmaceuticas que comprenden un derivado de pirimidina y ciclodextrina.
CA2135752A1 (en)	1993-12-09	Use of (E)-2-(p-Fluorophenethyl)-3-Fluoroallylamine in the Treatment of Alzheimer's Disease
CA2097878A1 (en)	1993-12-09	Therapeutic agent for neutropenia
NZ268039A (en)	1999-06-29	Use of efaroxan in treating parkinson's disease
RU93004536A (ru)	1996-06-10	Лекарство для профилактики и терапии неврологических и психиатрических нарушений, возникающих при употреблении алкоголя
IT1264428B1 (it)	1996-09-23	Composizioni farmaceutiche per il trattamento della psoriasi